Geneseeq's Breakthrough Cancer Detection Blood Test Published in Nature Medicine
Large-Scale Study Confirms CanScan ® Test Accurately Detects Early-Stage Cancers From a Simple Blood Draw
TORONTO, May 28, 2025 /CNW/ - Geneseeq is proud to announce the publication of results from its large-scale multi-cancer early detection (MCED) study in Nature Medicine, one of the world's leading peer-reviewed medical journals. The publication presents findings from the DECIPHE-Omnia Study (Detecting Early Cancer by Inspecting ctDNA Features), a landmark effort evaluating CanScan ®, Geneseeq's advanced blood-based test for early cancer detection.
Innovation Behind CanScan ®
CanScan ® is a non-invasive blood test powered by AI-driven whole-genome sequencing. It analyzes subtle cancer-specific changes in circulating cell-free DNA (cfDNA) using Geneseeq's proprietary MERCURY TM Technology. By integrating fragmentomics, genomic, and epigenomic features, the test identifies whether a cancer signal is present and accurately predicts the tissue of origin (TOO). In 2023, CanScan ® received Breakthrough Device Designation from the U.S. FDA.
A New Way to Catch Cancer Early
Unlike traditional cancer screening tools that are limited to one type of cancer and often involve invasive procedures, CanScan ® offers a convenient, comprehensive solution: a single blood test that screens for more than a dozen cancers at once.
In the study:
CanScan ® detected early-stage cancers with high accuracy
Identified cases missed by routine physical exams
Produced a low false-positive rate, helping reduce unnecessary follow-ups
"This study brings us closer to making routine multi-cancer screening a reality," said Dr. Yang Shao, CEO of Geneseeq. "Our vision is a future where a simple blood test can help save lives through earlier diagnosis."
The Landmark DECIPHER-Omnia Study
The DECIPHER-Omnia Study is a multi-phase clinical research program involving more than 8,000 participants to date across three stages:
Test development and training using samples from cancer patients and healthy donors
Independent clinical validation in a separate cohort
A large-scale ongoing screening study in asymptomatic individuals aged 45–75 (the JINLING cohort)
The newly published Nature Medicine paper presents interim findings from over 3,700 participants in the JINLING cohort.
Key Interim Results:
Specificity: 98.1%
Sensitivity: 53.5% across all detected cancers; 62.1% for targeted cancer types
Early-stage detection: 93% of confirmed cases were Stage 0, I, or II
Positive Predictive Value (PPV): 25% — 10 times higher than standard screening (2.2%)
Low false positives: Reduced unnecessary follow-up procedures
Detection of missed cancers: CanScan ® identified 53.3% of cancers overlooked by standard screening
Looking Ahead
The JINLING cohort study has now successfully completed enrollment of its target 15,000 participants and is currently in the follow-up and data analysis phase. The complete dataset, along with ongoing monitoring, is expected to provide deeper insights into the real-world utility of CanScan ® for population-level cancer screening.
Geneseeq Technology Inc. is a research-driven global leader in precision oncology, pioneering next-generation sequencing (NGS) technologies to transform cancer detection, diagnosis, and treatment. Its portfolio includes comprehensive genomic profiling for all tumor types, cancer-specific panels, minimal residual disease (MRD) monitoring, and multi-cancer early detection (MCED) solutions. Geneseeq has achieved several key regulatory milestones, including CE-IVD certification for its solid tumor and hematologic cancer panels, CE mark and FDA Breakthrough Device Designation for its MCED test, CanScan ®, and NMPA approval for two NGS-based IVD kits in lung cancer, including tumor mutational burden (TMB) detection. With headquarters in Canada and China, Geneseeq operates CAP- and CLIA-certified laboratories and partners with hospitals, research institutions, and pharmaceutical companies worldwide to advance precision medicine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
32 minutes ago
- Cision Canada
WORLD VAPE DAY 2025: LET'S CELEBRATE OUR PROGRESS AND KEEP WORKING TOWARDS A SMOKE FREE CANADA
OTTAWA, ON, May 30, 2025 /CNW/ - 2025 marks the 20 th anniversary of the first vapour products in North America. Rights4Vapers wishes to celebrate the lives saved thanks to these safer nicotine products as well as acknowledge that there is still much work to do to ensure that they remain available to adults who are looking for an alternative to deadly cigarettes. "Vaping saves lives. I hear it from Canadians who vape every day. I am one of them," said Maria Papaioannoy, spokesperson for Rights4Vapers, Canada's largest vaping and safer nicotine advocacy movement. "Despite being severely regulated. Despite misinformation campaigns from public health groups. Despite a continued and profound misunderstanding of nicotine. Despite push back against tobacco harm reduction. Vapour products are still here, thanks to the vocal advocacy of users." Vapes were invented in China in 2003 to deliver nicotine as a vapour, arriving in Europe and the US and Canada around 2005. Statistics Canada surveys between 2017 and 2022, revealed the smoking rate dropped by just over four percentage points, while the vaping rate increased by three. In just four years, approximately one million Canadians shifted their nicotine habits. Notably, daily smoking among teens has now fallen to under one percent. "Canadians who vape know that these products have saved their lives. Every Canadian adult who smokes deserves access to safer nicotine choices. This could be a vape, a pouch, gum or patch," said Ms. Papaioannoy. "Nicotine is not the villain. Combustion is. We need drastic reforms in how safer nicotine products are regulated." Rights4Vapers is calling on the federal government to develop a Safer Nicotine Act where all safer nicotine products are regulated fairly and equally, focusing on who needs them—not on who produces them. It's not the government's role to dictate how Canadians should quit smoking; it's the government's responsibility to ensure that all products are safe, regulated, and kept out of the hands of minors. Safer nicotine products including vapour products and nicotine pouches are the best hope for millions of Canadians who smoke and are looking for an alternative to cigarettes. In 2021, Public Health England released its latest review of vapour studies. It found that "the best thing that a smoker can do is to stop smoking completely and the evidence shows that vaping is one of the most effective quit aids available, helping around 50,000 smokers quit a year."
Cision Canada
2 hours ago
- Cision Canada
ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, May 30, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a Trial in Progress poster for its first-in-human, Phase 1a/1b clinical trial of IMGS-001 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 30 to June 3, 2025. This Phase 1a/1b first-in-human, open-label, multicenter study (NCT06014502) includes a dose escalation and an expansion portion to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. The study will enroll approximately 25 patients in Phase 1a and up to 250 in Phase 1b. The first three of five planned dose cohorts have completed without any dose limiting toxicities (DLTs), with cohort 4 (10 mg/kg) now enrolling. "This clinical trial is an important first step to understand how IMGS-001 may potentially remove immunosuppressive cells while improving PD-1 pathway blockade to treat otherwise immunoresistant tumors that represent a significant unmet medical need," stated Charles Schweizer, PhD, Senior Vice President of Clinical Development at ImmunoGenesis. "We are pleased to discuss the study plan and progress at this important conference as we look ahead to sharing results." "We are encouraged by the early performance of IMGS-001 as we proceed with Phase 1 dose escalation in patients with a variety of advanced solid tumors," said James Barlow, President and CEO of ImmunoGenesis. "Initial low doses administered to date have been well-tolerated with no dose-limiting toxicities, and we are seeing promising early signs of anti-tumor activity in patients who have failed prior treatments. IMGS-001 has the potential to be a foundational therapy for immune-excluded tumors, addressing a major unmet need." ASCO Poster Presentation Title: A Phase 1a/1b study to evaluate the safety, tolerability, Pharmakokinetics, and anti-tumor activity of IMGS-001 in Patients with relapsed or refractory advanced solid tumors. Abstract: TS2686 | Poster Bd #: 324a Track: Developmental Therapeutics—Immunotherapy Location: Hall A -Posters and Exhibits | On Demand Time: June 2, 2025, 1:30 PM – 4:30 PM CDT About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001, the lead program at ImmunoGenesis, is a PD-L1/PD-L2 dual-specific monoclonal antibody with engineered cytotoxic effector function. IMGS-001 is the first molecule in clinical testing to target PD-L2 in addition to PD-L1, potentially improving blockade of the PD-1 pathway. The engineered effector function may enable IMGS-001 to eliminate immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove higher response rates in head-to-head studies compared to currently available immunotherapies. IMGS-001 may provide a new foundational therapy with its innovative multitasking mechanism of superior blockade and cytotoxic effector function. IMGS-001 is being developed with support from the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094 as well as an investment from the Cancer Focus Fund, LP. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc.
Cision Canada
3 hours ago
- Cision Canada
MEDIA ADVISORY - Walking in Support of the 322,000+ people in Canada with Crohn's or colitis Français
Every 48 minutes – another Canadian is diagnosed with Crohn's or colitis; by 2035, 470,000+ Canadians will be living with IBD TORONTO, May 30, 2025 /CNW/ - WHAT: On Sunday, June 1, 2025, Crohn's and Colitis Canada, along with Canada's Inflammatory Bowel Disease (IBD) community, will participate in Gutsy Walk, a national fundraising event that supports the 322,000+ people living with Crohn's or colitis. Gutsy Walk, Crohn's and Colitis Canada's largest fundraising initiative, raises funds that go directly towards national research, advocacy, and patient programs. WHO: Those living with Crohn's or colitis, community members, friends, family and local representatives. WHEN: Sunday, June 1, 2025. Event start times may vary by location. WHERE: 30+ locations nationwide – from coast to coast. To register a team, donate and view locations, visit: WHY: There is no cure for Crohn's or colitis. Treatment focuses on achieving and maintaining remission, minimizing complications, preventing lasting intestinal damage, and improving quality of life. Crohn's and colitis are lonely diseases, with stigma and isolation added onto physical symptoms. SPOKESPERSON QUOTES: Jayda Sutton of Oakville, ON: Longstanding participant who lives with colitis and is the Ontario Provincial Honourary Chair. "I walk to honour my journey, my son Grayson who passed away at eight months gestation due to complications related to my colitis, my daughter Alyssa, my husband Chris, my parents and everyone who has stood with me. I want to use my story to highlight the quiet victories – getting back up when you feel defeated." Kate Lee, VP, Research & Patient Programs, Crohn's and Colitis Canada:"Gutsy Walk is a celebration of resilience. These are isolating diseases, which makes Gutsy Walk an important moment for those affected to come together and contribute to a better future for themselves." We are on a relentless journey to cure Crohn's and colitis and improve the quality of life of everyone affected by these diseases. Get the latest Gutsy Walk information on Instagram and Facebook - @gutsywalk and @getgutyscanada, as well as For information on Crohn's and Colitis Canada, visit
